<DOC>
	<DOC>NCT00215644</DOC>
	<brief_summary>The purpose of this study is to compare the effectiveness and safety of experimental treatment matuzumab and ECX chemotherapy, with ECX chemotherapy. Subjects invited to take part have metastatic cancer of the esophagus (gullet) or stomach.</brief_summary>
	<brief_title>MATRIX EG (Matuzumab Treatment With ECX in Esophago-Gastric Cancer)</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histologically confirmed gastric adenocarcinoma or adenocarcinoma of the lower third of the esophagus metastatic disease immunohistological evidence of EGFR expression from archived tissues ECOG PS 01 at least 1 measurable lesion (modified WHO criteria) previous chemotherapy, unless neoadjuvant or adjuvant therapy completed &gt; 12 months prior to study treatment radiotherapy or major surgery within 4 weeks prior to treatment brain metastases peripheral neuropathy or ototoxicity &gt;/= Grade 2 (NCICTC V3) abnormal ECG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Esophagus</keyword>
	<keyword>Gastric</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>EGFR</keyword>
	<keyword>matuzumab</keyword>
	<keyword>EMD 72000</keyword>
	<keyword>randomized</keyword>
	<keyword>Epirubicin</keyword>
	<keyword>cisplatin</keyword>
	<keyword>capecitabine</keyword>
	<keyword>Metastatic Esophago-Gastric cancer</keyword>
</DOC>